Novigenix

1. Executive Summary (Confidence: High)

Novigenix is a leader in "Immune Intelligence," recently completing a strategic spin-out in 2026 to separate its colorectal cancer (CRC) screening business from its biopharma-focused AI platform. The new entity, Novigenix AI, exclusively commercializes the LITOSeek platform, which analyzes whole-blood mRNA to predict therapy response and adverse event risks for checkpoint inhibitors and other immunotherapies. Backed by an ISO 13485-certified analytics platform and €1.8 million in EU funding from the BRECISE consortium, Novigenix is industrializing its AI solutions for prostate and bladder cancers. By shifting oncology from reactive to predictive, Novigenix provides a longitudinal view of patient immune status that traditional tissue biopsies cannot offer.